We have just finalized the results from the IASLC election of new members for the IASLC Board of Directors, and the results show a strong and broad representative new BOD, which will take office after the World Conference in Amsterdam. The voting percent of 56 among our members is the highest in IASLC history – and much higher than in many other large comparative organizations, which reflects a high engagement in our organization.
The New IASLC Bylaws passed the recent vote of the members.
Everyone should by now have received election material from the company Survey & Ballot Systems. If you have not received the ballot information, please contact the executive office email@example.com. Voting is now open (April 21 – May 26, 2011). Please vote as soon as possible.
I am happy to announce that more than 1900 abstracts have been submitted to the World Conference in Amsterdam, July 2011. That is a historical record for abstract submissions – and we are all looking forward to a very exciting conference! Please make your registration and travel plans as soon as possible.
The IASLC received many applications for the Fellowship/Young Investigators Awards from all over the world. The review procedure has started and final decisions will be expected at the IASLC BOD meeting in Santa Monica, CA February 26, 2011.
The IASLC is now preparing for election of new Board of Directors and the voting ballots will be sent out in April 2011.
The IASLC Fellowship/Young Investigator Award applications are due January 10, 2011. We would like to encourage as many as possible to apply for these fellowships/young investigator awards, particularly from Asia which has been underrepresented.
The World Lung Conference in Amsterdam July 3-7, 2011 is approaching and we would encourage members to start preparing this abstracts as early as possible. We expect this conference to be a historical success taking recent scientific developments in lung cancer screening and therapy into account.
Dear Colleagues: A few days ago the US National Cancer Institute (NCI) released initial results from the large-scale lung cancer screening trial; the National Lung Screening Trial (NLST), which demonstrated a 20% reduction in lung cancer mortality. This result will certainly lead to a significant change in clinical practice (see below).